PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, parallel-group study to compare the pharmacokinetics and
pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with
mild, moderate, and severe hepatic impairment (defined as Child-Pugh A, B, and C,
respectively) and matched healthy volunteers with normal hepatic function.